X4 Pharmaceuticals Inc represents a strong commitment to transforming the lives of patients through innovative therapies. With a focus on rare diseases and severe genetic disorders, the company aims to develop and commercialize treatments that address significant unmet medical needs. X4 Pharmaceuticals is driven by a core philosophy of scientific excellence, collaboration, and patient-centricity. By employing novel approaches and leveraging cutting-edge research, the company strives to deliver groundbreaking solutions that improve the quality of life for individuals facing challenging health conditions. With a strong emphasis on research and development, X4 Pharmaceuticals continues to pioneer advancements in the field of biotechnology.

X4 Pharmaceuticals Inc is primarily present in the United States.

X4 Pharmaceuticals Inc has achieved several significant milestones since its inception. Notably, the company successfully completed its initial public offering (IPO) in 2018, indicating investor confidence in its potential. Moreover, X4 Pharmaceuticals has made remarkable progress in the development of its lead candidate, X4P-001, for the treatment of various rare diseases. The company has initiated multiple clinical trials, showing promising results in the improvement of patients' condition. Additionally, X4 Pharmaceuticals has established strategic partnerships with renowned organizations to bolster research and development efforts further. These achievements highlight the commitment and expertise of X4 Pharmaceuticals Inc in advancing innovative therapies that address unmet medical needs.

X4 Pharmaceuticals Inc is a leading biopharmaceutical company focused on developing innovative therapies for rare diseases and cancer. Founded in 2015, X4 Pharmaceuticals has quickly gained recognition for its novel approach to targeting the body's immune system and restoring its natural ability to fight diseases. The company's groundbreaking research and development efforts center around developing small molecule drugs that selectively modulate chemokine receptors, controlling cellular migration and activation. With a diverse pipeline of potential therapies, X4 Pharmaceuticals is committed to delivering breakthrough treatments and improving the lives of patients worldwide.

The main competitors of X4 Pharmaceuticals Inc in the market include companies such as Company A, Company B, and Company C. These companies compete with X4 Pharmaceuticals Inc in terms of developing and commercializing innovative pharmaceutical products. With its unique approach and strong product pipeline, X4 Pharmaceuticals Inc aims to differentiate itself and capture a significant market share in the pharmaceutical industry. However, the competitive landscape remains dynamic, and market conditions may change over time.

X4 Pharmaceuticals Inc is primarily active in the biotechnology and pharmaceutical industries.

X4 Pharmaceuticals Inc operates under a business model focused on developing targeted therapies for rare genetic diseases and cancer. By leveraging its proprietary platform, X4P-001, the company aims to address serious unmet medical needs and improve patients' lives. X4 Pharmaceuticals Inc's innovative approach targets chemokine receptors to modulate the immune system and restore normal cellular function. With a mission to bring transformative advancements in precision medicine, X4 Pharmaceuticals Inc is committed to advancing its pipeline of promising drug candidates through rigorous research, clinical development, and strategic partnerships.

X4 Pharmaceuticals için şu anki KGV hesaplanamıyor.

X4 Pharmaceuticals için mevcut KUV şu anda hesaplanamıyor.

X4 Pharmaceuticals için AlleAktien Kalite Skoru 2/10'dur.

X4 Pharmaceuticals için şu an ciro hesaplanamıyor.

X4 Pharmaceuticals için şu anda kar hesaplanamıyor.

The X4 Pharmaceuticals Inc is a publicly traded biotechnology company from the USA that develops innovative therapies for rare diseases. The company is known for its groundbreaking research program in the field of immuno-oncology, inflammatory diseases, and primary immunodeficiencies. The X4 Pharmaceuticals Inc business model is based on the discovery, development, and commercialization of new drugs developed using new technologies. The company conducts research and development in collaboration with top academic institutions and independent laboratories. The company has various divisions, including research and development, production, and marketing. X4 Pharmaceuticals Inc focuses on the development of drugs targeting CXCR4 receptors. These are proteins responsible for controlling signals within the immune system. The company has developed several products, including X4P-001, a novel antibody therapeutic for cancer patients. X4P-001 targets CXCR4, a receptor that is overexpressed in many types of cancer and is considered responsible for disease progression. Another product that the company has developed is X4P-002. This medication is nearing clinical trials and is used for the treatment of primary immunodeficiencies and inflammatory diseases. X4P-002 has been recognized for its outstanding efficacy and tolerability in animal models. In addition to these products, X4 Pharmaceuticals Inc also has a comprehensive portfolio of patents to secure its technologies and products. The company has filed hundreds of patent applications for its drug candidates as well as its scientific research. X4 Pharmaceuticals Inc also operates production and business development units dedicated to reaching potential partners and investors for its technologies and drug candidates. By partnering with other pharmaceutical companies and scientific institutions, the company can expand and accelerate its product pipeline. Overall, the X4 Pharmaceuticals Inc business model is based on the discovery and development of new therapies for rare diseases through the exploration of novel technologies. The company aims to bring innovative and effective products to the market that can improve the lives of patients worldwide. With a dedicated and experienced leadership team and a team of experts in the field of biotechnology and medicine, X4 Pharmaceuticals Inc is on track to become one of the leading companies in the development of new drugs.

X4 Pharmaceuticals, yılda kez dağıtılmak üzere 0 USD tutarında temettü ödemektedir.

X4 Pharmaceuticals için şu an için temettü hesaplanamıyor veya şirket temettü dağıtmıyor.

X4 Pharmaceuticals şirketinin ISIN kodu US98420X1037’dir.

X4 Pharmaceuticals 'nin WKN'si A2PFVY 'dir.

X4 Pharmaceuticals için Ticker XFOR’dir.

Son 12 ay içerisinde X4 Pharmaceuticals, tutarında bir temettü ödedi. Bu, yaklaşık olarak oranında bir temettü verimine denk gelmektedir. Gelecek 12 ay için X4 Pharmaceuticals, tahmini olarak 0 USD tutarında bir temettü ödemesi yapacak.

X4 Pharmaceuticals şirketinin mevcut temettü verimi .

X4 Pharmaceuticals dönemsel olarak temettü ödemesi yapar. Bu ödemeler aylarında gerçekleştirilir.

X4 Pharmaceuticals, son 0 yıl içerisinde her yıl temettü ödedi.

Önümüzdeki 12 ay için 0 USD tutarında temettü ödenmesi beklenmektedir. Bu, 0 % oranında bir temettü verimidir.

X4 Pharmaceuticals, 'Sağlık' sektörüne atanmıştır.

Son X4 Pharmaceuticals tarihinde 0 USD tutarındaki en son temettüyü alabilmek için, hisseyi 08.11.2024 tarihindeki Ex-Tag'den önce portföyünde bulundurman gerekiyordu.

Son ödeme tarihi 08.11.2024 olarak gerçekleşti.

2023 yılında X4 Pharmaceuticals tarafından 0 USD olarak temettüler dağıtıldı.

X4 Pharmaceuticals hisselerinin temettüleri USD olarak dağıtılır.